ANNEX III

LABELLING AND PACKAGE LEAFLET

A. LABELLING

PARTICULARS TO APPEAR ON THE OUTER PACKAGE

Box with bottle of 60 ml

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

LEISGUARD 5 mg/ml Oral Suspension for Dogs
Domperidone

2. STATEMENT OF ACTIVE AND OTHER SUBSTANCES

Each ml contains:

Domperidone	5 mg
Methyl parahydroxybenzoate (E218)	1.80 mg
Propyl parahydroxybenzoate (E216)	0.20 mg
Quinoline yellow (E104)	0.20 mg

3. PHARMACEUTICAL FORM

Oral suspension

4. PACKAGE SIZE

60 ml

5. TARGET SPECIES

Dogs

6. INDICATION(S)

7. METHOD AND ROUTE(S) OF ADMINISTRATION

Read the package leaflet before use.

8. WITHDRAWAL PERIOD

9. SPECIAL WARNING(S), IF NECESSARY

Read the package leaflet before use

10. EXPIRY DATE

<EXP {month/year}>
Shelf-life after first opening the immediate packaging: 8 months

11. SPECIAL STORAGE CONDITIONS

Store in the original package.
Protect from light.

12. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCTS OR WASTE MATERIALS, IF ANY

Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal products should be disposed of in accordance with local requirements.

13. THE WORDS "FOR ANIMAL TREATMENT ONLY" AND CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE, if applicable

For animal treatment only. To be supplied only on veterinary prescription.

14. THE WORDS "KEEP OUT OF THE SIGHT AND REACH OF CHILDREN"

Keep out of the sight and reach of children.

15. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER

Marketing authorisation holder :
Laboratorios Dr. ESTEVE, S.A.
Av. Mare de Déu de Montserrat, 221
08041 – Barcelona (Spain)

16. MARKETING AUTHORISATION NUMBER(S)

17. MANUFACTURER'S BATCH NUMBER

<Batch> <Lot> <BN> {number}

PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS

Label of bottle

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

LEISGUARD 5 mg/ml Oral Suspension for Dogs
Domperidone

2. QUANTITY OF THE ACTIVE SUBSTANCE(S)

Domperidone 5 mg/ml, Methyl parahydroxybenzoate (E218), Propyl parahydroxybenzoate (E216), Quinoline yellow (E104)

3. CONTENTS BY WEIGHT, BY VOLUME OR BY NUMBER OF DOSES

60 ml

4. ROUTE(S) OF ADMINISTRATION

Oral use. Shake well before use. Read the package leaflet before use

5. WITHDRAWAL PERIOD

6. BATCH NUMBER

<Batch> <Lot> <BN> {number}

7. EXPIRY DATE

<EXP {month/year}>

8. THE WORDS "FOR ANIMAL TREATMENT ONLY"

For animal treatment only.

Disposal: read package leaflet
Keep the bottle in the outer carton to protect from light.

Marketing Authorisation Holder: Laboratorios Dr. Esteve, S.A., Barcelona (Spain)

B. PACKAGE LEAFLET

PACKAGE LEAFLET FOR:

LEISGUARD 5 mg/ml Oral Suspension for Dogs

1. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER AND OF THE MANUFACTURING AUTHORISATION HOLDER RESPONSIBLE FOR BATCH RELEASE, IF DIFFERENT

Marketing authorisation holder:
Laboratorios Dr. Esteve, S.A.
Av. Mare de Déu de Montserrat, 221
08041 – Barcelona (Spain)

Manufacturer responsible for batch release:
Laboratorios Dr. Esteve, S.A.
C) San Martí s/n - Polígono Industrial
08107 Martorelles, Barcelona

2. NAME OF THE VETERINARY MEDICINAL PRODUCT

LEISGUARD 5 mg/ml Oral Suspension for Dogs
Domperidone

3. STATEMENT OF THE ACTIVE SUBSTANCE(S) AND OTHER INGREDIENT(S)

Each ml contains:

Active substance:	
Domperidone	5 mg
Excipients:	
Methyl parahydroxybenzoate (E218)	1.80 mg
Propyl parahydroxybenzoate (E216)	0.20 mg
Quinoline yellow (E-104)	0.20 mg

Yellow suspension.

4. INDICATION(S)

To reduce the risk of developing an active infection and clinical disease after contact with *Leishmania infantum*, through the enhancement of the cell-mediated immune response.
The preventive efficacy has been demonstrated in dogs under multiple natural parasite exposure in zones with high infection pressure.

Control of clinical progression of canine leishmaniosis at early stages of the disease (dogs with low to moderate positive antibody levels and mild clinical signs such as peripheral lymphadenopathy or papular dermatitis).

5. CONTRAINDICATIONS

Do not use whenever stimulation of gastric motility might be dangerous eg. In the presence of gastrointestinal haemorrhage, mechanical obstruction or perforation.
Do not use in animals with a known hypersensitivity to domperidone or to any of the excipients.
Do not use in animals with prolactin-secreting pituitary tumor.

6. ADVERSE REACTIONS

In rare occasions, mammary gland disorders (mammary hyperplasia and milk production increase) have been observed. This is considered a consequence of the prolactine peaks induced by domperidone, which disappear after treatment discontinuation
In rare occasions, apathy and digestives signs (abdominal pain, diarrhoea, emesis, appetite loss) have been observed. These signs disappear once the treatment is withdrawn.

In very rare occasions, behavioural disorders have been observed.

***** The frequency of possible adverse effects is defined using the following convention:
very common (affects more than 1 animal in 10)
common (affects 1 to 10 animals in 100)
uncommon (affects 1 to 10 animals in 1,000)
rare (affects 1 to 10 animals in 10,000)
very rare (affects less than 1 animals in 10,000)
not known (frequency cannot be estimated from the available data).

If you notice any serious effects or other effects not mentioned in this leaflet, please inform your veterinary surgeon.

7. TARGET SPECIES

Dogs

8. DOSAGE FOR EACH SPECIES, ROUTE(S) AND METHOD OF ADMINISTRATION

0.5 mg/kg/d, equivalent to 1 ml/10 kg of Leisguard, once daily.

Shake well before use.

Leisguard may be administered directly into the mouth or mixed with food. To ensure a correct dosage, body weight should be determined as accurately as possible

PREVENTION:

In healthy animals, a treatment during 4 consecutive weeks induces an activation of the cell-mediated immune response leading to the establishment of an effective barrier against infection in case of eventual exposure to the parasite.

Therefore, in seronegative animals that have never showed any sign of *Leishmania spp*. infection, but live or travel to an endemic area, strategic domperidone treatments should be programmed, taking into account the temporary prevalence of leishmaniosis vectors *(Phlebotomus spp.)* in the geographic area of the patient location or destination.

In high prevalence areas or in climates with a long infective season, one treatment every fourth months is efficacious in preventing the infection and development of the disease. For optimum prevention in the Mediterranean area, it is advised to treat in June, October and February.
In low prevalence areas, one treatment period at the beginning of the infective season and another treatment shortly after its end may suffice.

In all cases, the treatment strategy must be established by the attending veterinarian in accordance with the local incidence of the disease and temporary presence of the infective vectors.

TREATMENT:

In seropositive animals with low to moderate positive antibody levels and mild clinical signs (such as peripheral lymphadenopathy or papular dermatitis), treatment during 4 consecutive weeks is effective for the control of the clinical progression of the disease. In these cases, Leisguard treatment should be started immediately after diagnosis in order to help animals to self-limit the disease. Improvement of clinical signs is gradually achieved during the following weeks after the end of treatment.

Treatment with Leisguard may be repeated as needed, in accordance with the clinical and serological follow up performed by the attending veterinarian.

9. ADVICE ON CORRECT ADMINISTRATION

Shake well before use

10. WITHDRAWAL PERIOD

Not applicable.

11. SPECIAL STORAGE PRECAUTIONS

Keep out of the sight and reach of children
Store in the original package.
Protect from light
Do not use this veterinary medicinal product after the expiry date which is stated on the carton after EXP.
The expiry date refers to the last day of that month.
Shelf-life after first opening the container: 8 months.

12. SPECIAL WARNING(S)

Special warning for each target species:
In case of severe infections, adequate aetiological treatment should be established in order to lower the parasitic load prior to consider a treatment with this veterinary product . In all cases,

and taking into account the highly variable evolution of the disease, close patient follow up is recommended in order to adapt the treatment to the clinical stage of the animal, as required.
Domperidone is metabolized by the liver, therefore it should not be administered to patients with liver failure

Special precautions for use in animals:
Administration of this veterinary medicinal product produces a transitory increase in plasma prolactin and could induce endocrine disturbances such as galactorrhoea. Therefore it should be used with caution in animals with previous episodes of pseudopregnancy.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:
People with known hypersensitivity to domperidone or to any of the excipients should avoid contact with the veterinary medicinal product.
In case of accidental ingestion, seek medical advice and show the package leaflet or the label to the physician.
If you develop symptoms following exposure such as skin rash, you should seek medical advice and show this warning to the physician. Swelling of the face, lips or eyes, or difficulty with breathing are more serious symptoms and require urgent medical attention.
Do not smoke, eat or drink while handling the product.

Use during pregnancy, lactation or lay:
Pregnancy - Reproduction studies were performed in laboratory animals with no evidence of drug related teratogenic or embryotoxic effects. Signs of maternal toxicity were not seen in laboratory animals at doses 20 times higher than the recommended dose. However, there are no adequate and well controlled studies in pregnant bitches; therefore this drug should be used during pregnancy only in accordance with the benefit/risk assessment by the responsible veterinarian.
Lactation - Administration of domperidone to lactating females of several species has been shown to induce an increase of milk production. Administration of Leisguard to lactating bitches is likely to induce the same effect.

Interaction with other medicinal products and other forms of interaction:
Cabergoline is a dopamine agonist that inhibits prolactin release from the pituitary gland. Therefore, its effects are antagonistic to those of domperidone.
Do not administer with stomach antacids such as omeprazole, cimetidine, or antacids
Domperidone should not be used with dopaminergic drugs such as dopamine or dobutamine

Overdose (clinical signs, emergency procedures, antidotes:
In tolerance trials performed in dogs, this veterinary medicinal product has been administered at five times the recommended doses during periods up to one year with no noticeable adverse events.

Incompatibilities:
In the absence of compatibility studies, this veterinary medicinal product must not be mixed with other veterinary medicinal products.

13. SPECIAL PRECAUTIONS FOR THE DISPOSAL OF UNUSED PRODUCT OR WASTE MATERIALS, IF ANY

Medicines should not be disposed of via wastewater or household waste.
Ask you veterinary surgeon how to dispose of medicines no longer required. These measures should help to protect the environment

14. DATE ON WHICH THE PACKAGE LEAFLET WAS LAST APPROVED

15. OTHER INFORMATION

Pack sizes:
Box with 1 bottle and 2 syringes 2, one graduated up to 1,5 ml and the other graduated up to 5 ml.

For any information about this veterinary medicinal product, please contact the local representative of the marketing authorisation holder.